Suwanee, GA - (NewMediaWire) - April 16, 2021 - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, announced today that the Company will be participating in a number of leading wound care industry conferences – both virtual and in-person – where it will highlight the clinical merits of its “Energy First” protocols and showcase how its end-to-end portfolio of non-invasive and biologic-response therapeutic solutions address the entire wound care continuum.SANUWAVE is currently scheduled to participate in the following industry events:SuperBones SuperWounds East 2021VirtualApril 17-18Advanced Wound Care Conference (AWCC)New Orleans, LAMay 7SAWC Spring Virtual Wound Care WeekVirtualMay 10-14LSI 2021 Emerging MedTech SummitDana Point, CAMay 11-13Wound Care Business Meetings 2021Philadelphia, PAJune 11Midwest Podiatry ConferenceVirtualJune 17-20Wound Care Business Meetings 2021Atlanta, GAJune 25“We are excited to share SANUWAVE’s new brands with the country’s leading wound care specialists at upcoming industry conferences, starting with the SuperBones event on April 18th, where we will discuss the coding, billing and reimbursement for our ‘Energy First’ products,” stated Kevin A. Richardson, II, Chairman and Chief Executive Officer of SANUWAVE Health. “SANUWAVE will continue to educate the industry on the clinical merits of our ‘Energy First’ products and how they improve clinical outcomes for those patients with chronic, non-healing wounds. We invite everyone to visit us at our booths at these conferences—whether virtual or in-person—and learn what the new SANUWAVE suite of solutions has to offer.” About SANUWAVE SANUWAVE Health, Inc. (OTCQB: SNWV) is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medical products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac/endovascular conditions. For more information, please visit. www.SANUWAVE.com.Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief, or current expectations of the company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions, and factors that may affect operating results, performance, and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.Media CONTACT: Jane ByramSCORR Marketing512.626.2758jane@scorrmarketing.com
NEW YORK, NY - (NewMediaWire) - April 16, 2021 - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today showcased the blister pack design for its newest, proprietary, Tauri-Gum™ SKU. The Company is currently in production for its Evergreen Mint flavor, Delta 8 Tetrahydrocannabinol (“Delta 8 THC”) infused, version of Tauri-Gum™. Each piece of chewing gum is infused with 10mg Delta 8 THC and the MSRP (per Blister Pack) is set at $18.99.In other news, the Company has been approved to participate in a large scale, human safety Study, administered by Validcare -- to Gather Data for FDA. The Company’s Cannabinoid based Pharmaceutical -- Anti-Nausea -- chewing gum, is being included in Cohort 2 of this Study (IRB approved Study). Please See Below Press Release Link (04/15/2021):https://www.prnewswire.com/news-releases/validcare-announces-a-second-cohort-of-cbd-brands-joins-safety-study-to-gather-data-for-fda-301270259.htmlABOUT TAURIGA SCIENCES INC.Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.comComplementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.DISCLAIMER -- Forward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to ...
